PMAM
ADMA icon

Picton Mahoney Asset Management’s ADMA Biologics ADMA Stock Holding History

Picton Mahoney Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64
Closed -$577 – 1383
2026
Q1 		$577 Sell
64
-230,752
-100% -$3.64M ﹤0.01% 1225
2025
Q4 		$4.21M Sell
230,816
-133,222
-37% -$2.25M 0.03% 353
2025
Q3 		$5.34M Sell
364,038
-73,679
-17% -$1.26M 0.05% 270
2025
Q2 		$7.97M Buy
437,717
+305,149
+230% +$6.22M 0.08% 217
2025
Q1 		$2.63M Buy
132,568
+132,504
+207,038% +$2.29M 0.05% 227
2024
Q4 		$1K Sell
64
-2,800
-98% -$52.7K ﹤0.01% 596
2024
Q3 		$57K Buy
+2,864
New +$44.5K ﹤0.01% 368

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Picton Mahoney Asset Management's ADMA Position: Q2 2026 in Review

Picton Mahoney Asset Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 64 shares — an estimated $577 sold.

Picton Mahoney Asset Management first reported a position in ADMA in Q3 2024 and held it in 7 quarters. The position peaked at $7.97M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Picton Mahoney Asset Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 64 ADMA Biologics shares in Q2 2026, an estimated $577.
  • Picton Mahoney Asset Management first reported a position in ADMA Biologics in Q3 2024 and held it in 7 quarters.
  • Picton Mahoney Asset Management's ADMA Biologics position peaked at $7.97M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.